Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a price target of $102.00.
A microbiologist in protective gear studying samples in a laboratory.
On June 25, Viking Therapeutics, Inc. announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, which is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Management reported that VK2375 is under development in both subcutaneous and oral formulations to potentially treat metabolic disorders such as obesity.
The VANQUISH Phase 3 program encompasses two studies evaluating VK2735: one in obese or overweight adults with type 2 diabetes and one in adults with obesity.
Viking Therapeutics, Inc. is a clinical-stage company that develops therapies for metabolic and endocrine disorders.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.